Thursday, October 21, 2021

U.S. FDA authorizes third dose of Pfizer COVID-19 vaccine for older Americans

Must read

imageWorld8 minutes ago (Sep 22, 2021 08:00PM ET)

(C) Reuters. FILE PHOTO: A health worker draws a dose of Pfizer-BioNTech coronavirus disease (COVID-19) vaccine from a vial during a vaccination event hosted by Miami – Dade County and Miami Heat, at FTX Arena in Miami, Florida, U.S., August 5, 2021. REUTERS/Marco Bel

(Reuters) -The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc (NYSE:PFE) and BioNTech COVID-19 vaccine for those aged 65 and older and some high-risk Americans, paving the way for a quick rollout of the shots.

The booster dose is to be administered at least six months after completion of the second dose, and the authorization would include people most susceptible to severe disease and those in jobs that left them at risk, the FDA said.

A U.S. Centers for Disease Control and Prevention (CDC) advisory panel could vote on Thursday on the use of a third shot of the vaccine, an agency official said at a public meeting of the panel on Wednesday.

President Joe Biden announced in August the government’s intention to roll out booster shots for people aged 16 and older this week, pending approval by the FDA and CDC.

Advisers to the FDA voted on Friday to recommend COVID-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, after overwhelmingly rejecting a call for broader approval.

The advisory panel said there was not enough evidence to support booster shots for all those aged 16 and older who had received a second dose at least six months earlier and also sought more safety data.

The agency could revisit the issue of additional shots for a broader authorization in the future. Top FDA members have been split on the need for boosters for the general population, with interim head Janet Woodcock backing them and some of the agency’s senior scientists arguing current evidence does not support them.

Johnson & Johnson (NYSE:JNJ) said on Tuesday a second shot of its COVID-19 vaccine increased its effectiveness in the United States against moderate to severe forms of the disease.

Data from Moderna (NASDAQ:MRNA) Inc’s COVID-19 vaccine on booster doses is just weeks away, President Joe Biden’s chief medical adviser, Dr. Anthony Fauci, said on Sunday.

Some countries, including Israel and Britain, have already rolled out COVID-19 booster campaigns. The United States authorized extra shots for people with compromised immune systems last month and over 2 million people had already received a third shot, CDC data showed.

U.S. FDA authorizes third dose of Pfizer COVID-19 vaccine for older Americans

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Latest article

SUBSCRIBE HERE